AMGN Share Price

Open 159.71 Change Price %
High 161.60 1 Day 1.58 0.99
Low 159.64 1 Week 2.06 1.30
Close 160.57 1 Month -9.14 -5.39
Volume 3357451 1 Year -2.10 -1.29
52 Week High 176.85
52 Week Low 0.00
AMGN Important Levels
Resistance 2 162.39
Resistance 1 161.64
Pivot 160.60
Support 1 159.50
Support 2 158.75
NASDAQ USA Most Active Stocks
SIRI 4.11 -3.07%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
GRPN 4.10 -22.05%
NXPI 99.08 0.43%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
RITT 0.06 50.00%
ZAZA 0.06 50.00%
LTBR 1.62 35.00%
SCHS 0.12 33.33%
ALTI 0.13 30.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

Amgen Inc. (NASDAQ: AMGN)

AMGN Technical Analysis 2
As on 27th Oct 2016 AMGN Share Price closed @ 160.57 and we RECOMMEND Buy for LONG-TERM with Stoploss of 158.65 & Strong Sell for SHORT-TERM with Stoploss of 168.78 we also expect STOCK to react on Following IMPORTANT LEVELS.
AMGN Target for October
1st Target up-side 173.13
2nd Target up-side 177.55
3rd Target up-side 181.98
1st Target down-side 160.49
2nd Target down-side 156.07
3rd Target down-side 151.64
AMGN Other Details
Segment EQ
Market Capital 67280416768.00
Sector Healthcare
Industry Biotechnology
Offical website
AMGN Address
One Amgen Center Drive
Thousand Oaks, CA 91320
United States
Phone: 805-447-1000
Fax: 805-447-1010
Interactive Technical Analysis Chart Amgen Inc. ( AMGN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Amgen Inc.
AMGN Business Profile
Amgen Inc., incorporated on October 31, 1986, is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the outstanding stock of deCODE Genetics (deCODE). In July 5, 2012, the Company acquired KAI Pharmaceuticals, a privately held company based in South San Francisco. In June 12, 2012, the Company acquired substantially all of the outstanding stock of Mustafa Nevzat Pharmaceuticals (MN). In March 7, 2012, the Company acquired Micromet, Inc. (Micromet), a publicly held biotechnology company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. In September 2013, Swedish Orphan Biovitrum AB (publ) (Sobi) announced that they have acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen Inc for all therapeutic indications. The Company’s principal products include Neulasta, NEUPOGEN, ENBREL, Aranesp, EPOGEN, XGEVA and Prolia. Its principal products are Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), both of which stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection); Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in inflammatory diseases; Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa), erythropoiesis-stimulating agents (ESAs) that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab), two products that contain the same active ingredient but which are approved for different indications, patient populations, doses and frequencies of administration. In addition to its marketed products, the Company has various product candidates in mid-to late-stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience.